A novel multimeric<scp>sCD19</scp>‐streptavidin fusion protein for functional detection and selective expansion of<scp>CD19</scp>‐targeted<scp>CAR‐T</scp>cells-Reference-Cited by-同舟云学术

A novel multimericsCD19‐streptavidin fusion protein for functional detection and selective expansion ofCD19‐targetedCAR‐Tcells

Published:2022-05-27 Issue:15 Volume:11 Page:2978-2989
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Lian Hui¹²,Jiang Jinhong³,Wang Yao²,Yu Xiaoxiao²,Zheng Rong²,Long Jing²,Zhou Mengjie²,Zhou Shirong²,Wei Cheng²,Zhao Ai⁴,Gao Jimin²⁵^ORCID

Affiliation:

1. The First People's Hospital of Linping District Hangzhou Zhejiang China

2. Zhejiang Provincial Key Laboratory for Technology and Application of Model Organisms, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences Wenzhou Medical University Wenzhou Zhejiang China

3. Department of Hematology, Lishui People's Hospital Sixth Affiliated Hospital of Wenzhou Medical University Lishui Zhejiang China

4. Department of Geriatric, Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China

5. Zhejiang Qixin Biotech Wenzhou China

Funder

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4657

Reference41 articles.

1. CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients

2. Synthetic immunology: T-cell engineering and adoptive immunotherapy

3. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

4. Engineering CAR-T cells: Design concepts

5. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of tumor immunotherapy based on approved drugs;Life Sciences;2024-03